EUVIMEDEUVIMED entdecken
Crossref

Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark ‐2 study

Citadel J Cabasag iD, Melina Arnold, Mark Rutherford, Jacques Ferlay iD, Aude Bardot, Eileen Morgan iD, John Butler, Dianne L O'Connell, Gregg Nelson, Claus Høgdall, Tine Schnack, Anna Gavin und 16 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Citadel J Cabasag und 27 weiteren Autor:innen. Beteiligte Einrichtung: International Agency for Research on Cancer, Lyon, France. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: World Health Organization, Cancer Research UK, Cancer Council Victoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15‐64 and 65‐99 years). Net survival (NS) was estimated by subtype, age group and 5‐year period using Pohar‐Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma “not otherwise specified” with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20‐year study period in all countries with 5‐year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansFemaleAgedCarcinoma, Ovarian EpithelialIncidenceUnited KingdomNorwayRegistries

Stichwörter der Autor:innen

cancer surveillanceepithelial ovarian cancerhistological subtypenet survivalpopulation-based

Autor:innen und Institutionen

  • International Agency for Research on Cancer, Lyon, France.
  • Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK.
  • Northern Ireland Cancer Registry, Center for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
  • Royal Marsden Hospital, London, England, UK.
  • The Daffodil Center, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
  • Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Citadel J Cabasag, Jacques Ferlay, Eileen Morgan, Charlie Gourley, Freddie Bray, Isabelle Soerjomataram

Förderung

  • World Health Organization
  • Cancer Research UK
  • Cancer Council Victoria
  • Cancer Institute NSW
  • Kræftens Bekæmpelse
  • Kreftforeningen
  • Partenariat Canadien Contre Le Cancer
  • Public Health Wales

Zitieren

APA

Cabasag, C. J., Arnold, M., Rutherford, M., Ferlay, J., Bardot, A., Morgan, E., Butler, J., O'Connell, D. L., Nelson, G., Høgdall, C., Schnack, T., Gavin, A., Elwood, M., Hanna, L., Gourley, C., De, P., Saint-Jacques, N., Mørch, L. S., Woods, R. R., …, & Soerjomataram, I. (2023). Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark ‐2 study. International Journal of Cancer. https://doi.org/10.1002/ijc.34403

Vancouver

Cabasag CJ, Arnold M, Rutherford M, Ferlay J, Bardot A, Morgan E, et al. Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark ‐2 study. International Journal of Cancer. 2023. doi:10.1002/ijc.34403

BibTeX
@article{Cabasag2023,
  author = {Cabasag, Citadel J and Arnold, Melina and Rutherford, Mark and Ferlay, Jacques and Bardot, Aude and Morgan, Eileen and Butler, John and O'Connell, Dianne L and Nelson, Gregg and Høgdall, Claus and Schnack, Tine and Gavin, Anna and Elwood, Mark and Hanna, Louise and Gourley, Charlie and De, Prithwish and Saint-Jacques, Nathalie and Mørch, Lina Steinrud and Woods, Ryan R and Altman, Alon D and Sykes, Peter and Cohen, Paul A and McNally, Orla and Møller, Bjørn and Walsh, Paul and Morrison, David S and Bray, Freddie and Soerjomataram, Isabelle},
  title = {Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark ‐2 study},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34403}
}
Kostenlos starten →